1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

RDY
Dr. Reddy's Laboratories LimitedUS flagNew York Stock Exchange
11.97
USD
-0.06
- -
9.97BMarket Cap

Total Valuation

Dr. Reddy's Laboratories Limited carries a market capitalization of 9.97B, placing it among publicly traded companies globally. Its enterprise value stands at 1.14T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap9.97B
Enterprise Value1.14T

Share Statistics

Dr. Reddy's Laboratories Limited currently has 832.98M shares outstanding.

Shares Outstanding832.98M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Dr. Reddy's Laboratories Limited trades at a trailing price-to-earnings ratio of 34.47. The price-to-sales ratio is 3.45, and the price-to-book ratio stands at 2.98.

PE Ratio34.47
PS Ratio3.45
PB Ratio2.98
P/TBV Ratio4.28
P/FCF Ratio15.60
P/OCF Ratio27.71

Enterprise Valuation

On an enterprise value basis, Dr. Reddy's Laboratories Limited trades at an EV/EBITDA multiple of 27.40 and an EV/FCF ratio of 14.84. The EV/Sales ratio of 3.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 31.48 provides insight into valuation relative to core operating earnings.

EV / Sales3.43
EV / EBITDA27.40
EV / EBIT31.48
EV / FCF14.84

Financial Position

Dr. Reddy's Laboratories Limited maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.60, indicating elevated leverage, while an interest coverage ratio of 9.95 demonstrates adequate ability to service its debt obligations.

Current Ratio1.90
Quick Ratio1.31
Debt / Equity18.60
Debt / EBITDA1.74
Interest Coverage9.95

Financial Efficiency

Dr. Reddy's Laboratories Limited posts a return on equity of 9.03 and a return on invested capital of 6.55.

Return on Equity (ROE)9.03
Return on Assets (ROA)6.05
Return on Invested Capital (ROIC)6.55
Return on Capital Employed (ROCE)8.55
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.55

Taxes

Over the trailing twelve months, Dr. Reddy's Laboratories Limited has paid 8.58B in income taxes, reflecting an effective tax rate of 20.77.

Income Tax8.58B
Effective Tax Rate20.77

Stock Price Statistics

Dr. Reddy's Laboratories Limited's stock has declined approximately -16.05891% over the past 52 weeks. The 50-day moving average sits at 12.61, while the 200-day moving average is 13.46.

Beta (5Y)N/A
52-Week Price Change-16.05891%
50-Day Moving Average12.61
200-Day Moving Average13.46
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Dr. Reddy's Laboratories Limited generated 331.19B in revenue and converted that into 33.11B in net income, yielding earnings per share of 39.27. EBITDA reached 41.43B, while operating income came in at 36.06B.

Revenue331.19B
Gross Profit175.52B
Operating Income36.06B
Pretax Income41.30B
Net Income33.11B
EBITDA41.43B
EBIT36.06B
Earnings Per Share (EPS)39.27

Balance Sheet

Dr. Reddy's Laboratories Limited holds 81.43B in cash and equivalents against 71.95B in total debt, resulting in a net debt position of 46.48B. Total book value stands at 383.43B, with working capital of 141.99B providing operational flexibility.

Cash & Cash Equivalents81.43B
Total Debt71.95B
Net Debt46.48B
Equity (Book Value)383.43B
Book Value Per Share460.31
Working Capital141.99B

Cash Flow

Dr. Reddy's Laboratories Limited produced 41.20B in operating cash flow over the past twelve months. After subtracting -31.98B in capital expenditures, free cash flow totaled 9.22B - equivalent to 11.07 per share.

Operating Cash Flow41.20B
Capital Expenditures-31.98B
Free Cash Flow9.22B
FCF Per Share11.07

Margins

Dr. Reddy's Laboratories Limited operates with a gross margin of 86.97, reflecting its pricing power and cost economics. The operating margin of 10.89 and net profit margin of 10.00 provide insight into operational efficiency.

Gross Margin86.97
Operating Margin10.89
Pretax Margin12.47
Profit Margin10.00
EBITDA Margin12.51

Dividends & Yields

The company's payout ratio of 20.59 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share7.99
Dividend YieldN/A
Payout Ratio20.59
Shareholder Yield-0.21
FCF Yield6.41

Stock Splits

Dr. Reddy's Laboratories Limited's most recent stock split took place on November 5, 2024 with a 1:5 split ratio.

Last Split Date11/5/2024
Split Ratio1:5

Scores

Dr. Reddy's Laboratories Limited posts an Altman Z-Score of 6.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.07